DMRA
Damora Therapeutics, Inc.
20.20$
-2.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -23.6% | -15.0% | -15.9% | -14.4% | -26.7% | -10.3% | -10.9% | -21.6% | +2,326.7% | +105.5% | +1.5% | |
| – | -21.8% | -16.9% | -17.6% | -15.9% | -20.5% | -20.4% | -13.8% | -15.3% | +2,561.2% | +105.6% | +1.5% | |
| – | -7.0% | -1.7% | +8.4% | -13.9% | -28.0% | -15.8% | -14.5% | -25.5% | +3,287.1% | +106.9% | +1.4% | |
| – | -25.0% | -18.0% | -15.9% | -13.9% | -28.0% | -15.8% | -14.5% | -25.5% | +3,287.1% | +106.9% | +1.4% | |
| – | +43.2% | -0.9% | +1.1% | -30.0% | -26.9% | +4.1% | +7.7% | +0.4% | -9.4% | -0.6% | -1.6% | |
| – | -53.5% | -26.8% | -14.1% | -34.2% | +9.0% | +13.3% | +35.2% | -0.2% | +395.0% | +25.0% | +9.5% | |
| – | -53.6% | -25.9% | -14.1% | -34.2% | -51.0% | +29.6% | +69.5% | -0.2% | +665.0% | +18.7% | +15.7% | |
| – | -48.0% | -15.3% | -50.3% | -58.4% | -62.5% | +8.3% | +15.4% | +0.0% | +0.0% | – | – | |
| – | -62.0% | -2.2% | -56.5% | -30.5% | -25.0% | -6.1% | +113.6% | -31.2% | -14.6% | +84.5% | +325.2% | |
| – | -13.5% | -12.9% | -16.2% | -11.2% | -30.9% | -14.7% | -22.2% | -30.6% | +3,506.1% | +112.3% | +1.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +5.6% | +12.7% | +2.5% | +0.0% | +0.3% | +24.9% | +1,969.2% | +78.2% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.